KAIYUAN SECURITIES·2025-08-17 10:15Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the transformation of China's medical insurance system from a "single basic coverage" model to a "basic insurance + commercial insurance supplementary" dual-track system, marked by the introduction of the commercial insurance innovative drug directory [5][13] - The commercial insurance innovative drug directory primarily focuses on high-value innovative drugs in oncology, immunology, and rare diseases, providing a new pathway for these drugs to gain market access [6][20] - The report indicates that the inclusion of innovative drugs in both the basic and commercial insurance directories is expected to lead to rapid revenue growth for related companies, benefiting patients and driving growth for innovative pharmaceutical firms [6][29] Summary by Sections Section 1: National Drug Review and Commercial Insurance Directory - The announcement of the national drug review results and the debut of the commercial insurance innovative drug directory occurred on August 12, 2025, indicating a significant policy shift [5][13] - The commercial insurance directory includes 121 drugs, focusing on those with high clinical value and significant patient benefits, particularly in oncology and rare diseases [20][27] - The report emphasizes that the commercial insurance directory allows for a more flexible pricing mechanism, which does not count towards hospital drug expenditure ratios, thus facilitating the market entry of high-value innovative drugs [28][24] Section 2: Market Performance and Trends - In August 2025, the pharmaceutical and biotechnology sector saw a 3.08% increase, outperforming the CSI 300 index by 0.7 percentage points [2][10] - The medical research outsourcing sector experienced the highest growth, while the offline pharmacy sector faced declines [10][12] - The report notes that the inclusion of over 20 traditional Chinese medicines in the 2025 basic medical insurance directory, primarily unique products, reflects a growing recognition of traditional medicine [6][29] Section 3: Recommended Stocks and Beneficiaries - Recommended stocks in the pharmaceutical and biotechnology sector include companies such as Heng Rui Medicine, East China Medicine, and Innovent Biologics, among others [7] - The report also highlights potential beneficiaries in the CXO sector, including WuXi AppTec and Tigermed, as well as companies in the medical device and service sectors [7][29]